Search results for "Progression"

showing 10 items of 1251 documents

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, m…

2016

BACKGROUND: Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease.METHODS: We enrolled 208 patients with classical Hodgkin's lymphoma and treated with ABVD (training set), from Jan 1, 2002, to Dec 31, 2009, and validated the results in a fully matched independent cohort of 102 patients with classical Hodgkin's lymphoma (validation set), enrolled from Jan 1, 2008, to De…

OncologyMaleDenmarkProgrammed Cell Death 1 ReceptorCohort Studies0302 clinical medicineRecurrenceAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentMedicineTreatment FailureReed-Sternberg CellsHazard ratioHematologyHodgkin DiseaseVinblastineDacarbazineSTAT1 Transcription FactorItalylymphoma PET Hodgkin030220 oncology & carcinogenesisDisease ProgressionbiomarkerFemalemedicine.drugAdultmedicine.medical_specialtyDacarbazineAntigens Differentiation MyelomonocyticSettore MED/08 - Anatomia PatologicaVinblastineDisease-Free Survival03 medical and health sciencesBleomycinAntigens CDInternal medicineHumansRetrospective StudiesFluorodeoxyglucosebusiness.industryRetrospective cohort studyPET scanmedicine.diseaseLymphomaSurgeryABVDReed–Sternberg cellDoxorubicinPositron-Emission TomographyMultivariate Analysisclassical Hodgkin's lymphoma:PolandbusinessBiomarkers030215 immunology
researchProduct

Prophylactic cranial irradiation in stage IV small cell lung cancer

2019

Background: Due to conflicting results between major trials the role of prophylactic cranial irradiation (PCI) in stage IV small cell lung cancer (SCLC) is controversial.Methods: We obtained a list of 13 European experts from both the European Society for Therapeutic Radiation Oncology (ESTRO) and the International Association for the Study of Lung Cancer (IASLC). The strategies in decision making for PCI in stage IV SCLC were collected. Decision trees were created representing these strategies. Analysis of consensus was performed with the objective consensus methodology.Results: The factors associated with the recommendation for the use of PCI included the fitness of the patient, young age…

OncologyMaleESTRO; Expert opinion; IASLC; PCI; Small cell lung cancer; Stage IV; Hematology; Oncology; Radiology Nuclear Medicine and ImagingLung Neoplasmsmedicine.medical_treatmentMedizin030218 nuclear medicine & medical imaging0302 clinical medicineQUALITY-OF-LIFENuclear Medicine and ImagingESTRO610 Medicine & healthStage IVHematologyBrain NeoplasmsRadiation OncologistsPCIHematologyMiddle AgedProgression-Free SurvivalExpert opinion030220 oncology & carcinogenesisFemaleTRIALNon small cellRadiologyAdultmedicine.medical_specialtyDecision Making03 medical and health sciencesInternal medicinemedicineHumansIASLCRadiology Nuclear Medicine and imagingLung cancerAgedNeoplasm StagingChemotherapySmall cell lung cancerbusiness.industryPatient Selectionmedicine.diseaseONCOLOGYSmall Cell Lung CarcinomaYoung ageConventional PCIProphylactic cranial irradiationCranial IrradiationbusinessStage ivRadiotherapy and Oncology
researchProduct

FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unk…

2021

Abstract Background Poorly differentiated neuroendocrine carcinomas (NEC) are rare diseases with a poor prognosis. Platinum-etoposide (PE) has been the recommended first-line treatment for decades. FOLFIRINEC (NCT04325425) is a national multicenter randomized phase II study which aims to challenge this standard regimen. Methods The primary objective is to compare the median progression-free survival (PFS) under mFOLFIRINOX versus PE. The secondary objectives are to evaluate the objective response rates (ORR), median overall survival (OS), safety and quality of life. The associated real-time translational study will establish a molecular profile for each patient enrolled. Main inclusion crit…

OncologyMaleFOLFIRINOXmedicine.medical_treatmentLeucovorinPhases of clinical researchPlatinum Compounds0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesNeoplasm MetastasisEtoposideEtoposideGastroenterologyEvaluable DiseaseProgression-Free Survival3. Good healthFOLFIRINOXOxaliplatinSurvival RateNeuroendocrine TumorsTreatment Outcome030220 oncology & carcinogenesisNeuroendocrine carcinoma030211 gastroenterology & hepatologyFemaleFluorouracilmedicine.drugAdultmedicine.medical_specialtyIrinotecanGastroenteropancreatic03 medical and health sciencesStomach NeoplasmsInternal medicineIntestinal NeoplasmsmedicineChemotherapyHumansContraindicationChemotherapyHepatologyPerformance statusbusiness.industry[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyCarcinoma NeuroendocrinePancreatic NeoplasmsRegimenQuality of LifeNeoplasms Unknown PrimarybusinessBiomarkersDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

2012

Background: Scientific data provide the evidence that secondary K-RAS mutations do not occur during anti-epidermal growth factor receptor therapy in colorectal cancer patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. Patients and methods: We enrolled 39 irinotecan-refractory patients who had a clinical benefit after a line of cetuximab- plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were retreated with the same cetuximab- plus irinotecan-based therapy. Results: Median number of therapeutic li…

OncologyMaleLung NeoplasmsColorectal cancerSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntibodieCetuximab; Clinical trial; Colorectal neoplasms; Phase II; RetreatmentDrug ResistanceCetuximabadverse effects/pharmacology/therapeutic useAdult; Aged; 80 and over; Antibodies; Monoclonal; administration /&/ dosage; Antineoplastic Combined Chemotherapy Protocols; adverse effects/pharmacology/therapeutic use; Camptothecin; administration /&/ dosage/analogs /&/ derivatives; Colorectal Neoplasms; drug therapy/mortality/pathology; Disease-Free Survival; Drug Resistance; Neoplasm; Exanthema; chemically induced; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; drug therapy/mortality/secondary; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Treatment OutcomeColorectal NeoplasmKaplan-Meier EstimateAntineoplastic Combined Chemotherapy ProtocolsMonoclonal80 and overProspective cohort studyadministration /&/ dosageAged 80 and overCetuximabLiver NeoplasmsAntibodies MonoclonalHematologyMiddle AgedChemotherapy regimenPhase IIClinical trialTreatment OutcomeOncologyLiver NeoplasmLymphatic MetastasisRetreatmentchemically inducedFemaleColorectal Neoplasms/ dosage/analogs /&ampmedicine.drugHumanAdultmedicine.medical_specialtyAntibodies Monoclonal HumanizedIrinotecanAntibodiesDisease-Free SurvivalColorectal neoplasmdrug therapy/mortality/secondarySDG 3 - Good Health and Well-beingInternal medicineadministration /&/ dosage/analogs /&/ derivativesmedicine/ dosageHumansProgression-free survivalneoplasmsAgeddrug therapy/mortality/pathologyChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryLymphatic MetastasiExanthemamedicine.diseasedigestive system diseasesIrinotecanClinical trialLung Neoplasm/ derivativeDrug Resistance Neoplasmadministration /&ampNeoplasmCamptothecinbusinessAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a …

2014

Contains fulltext : 153742.pdf (Publisher’s version ) (Closed access) BACKGROUND: The impact of prognostic factors in T1G3 non-muscle-invasive bladder cancer (BCa) patients is critical for proper treatment decision making. OBJECTIVE: To assess prognostic factors in patients who received bacillus Calmette-Guerin (BCG) as initial intravesical treatment of T1G3 tumors and to identify a subgroup of high-risk patients who should be considered for more aggressive treatment. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data were collected for 2451 T1G3 patients from 23 centers who received BCG between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Using Cox multivariable re…

OncologyMaleNon–muscle-invasive bladderBacillus Calmette-Guerin; BCG; Non-muscle-invasive bladder cancer; Prognostic factors; T1G3Settore MED/24 - UrologiaRisk groupsRetrospective StudieRisk FactorsBCGAge Factorskin and connective tissue diseasesBacillus Calmette-GuerinBacillus (shape)Prognostic factorbiologyBacillus Calmette-Gue´rin BCG Non–muscle-invasive bladder cancer Prognostic factors T1G3Age FactorsBacillus Calmette-Gue´rinMiddle AgedPrognosisTumor BurdenBacilluSurvival RateUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Urinary Bladder NeoplasmBCG VaccineDisease ProgressionFemaleNon muscle invasiveCalmette-GuérinCarcinoma in SituHumanmedicine.medical_specialtyPrognosiNon-muscle-invasive bladder cancerUrologyUrologyT1G3Prognostic factorsCystectomyRisk AssessmentNon–muscle-invasive bladder cancerFollow-Up StudieAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicinecancerHumansAgedRetrospective StudiesBladder cancerbusiness.industryRisk Factorbiology.organism_classificationmedicine.diseaseMulticenter studyUrinary Bladder NeoplasmsProper treatmentNeoplasm Recurrence LocalbusinessFollow-Up StudiesEuropean urology
researchProduct

Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a stu…

2012

Background: Hypothesising that cancer of unknown primary (CUP) may harbour unique characteristics, we present a translational study of the immunohistochemical expression and clinical correlation of key PTEN/AKT pathway molecules. Patients and methods: We collected 100 paraffin-embedded CUP tissue blocks. We studied using tissue microarrays the expression of PTEN, phospho-AKT, Cyclin D1, p21, phospho-RPS6. From the percentage of staining tumour cells and the literature, we selected cut-offs to classify the expression of each biomolecule. We correlated IHC expression with clinical data. Results: PTEN, pAKT, and pRPS6 showed frequent expression. At univariate analysis, high IHC expression of p…

OncologyMalePathologyP21Signal transductionMitogen activated protein kinaseTissue microarrayCancer riskNeoplasmsSquamous cell carcinomaCarcinomatous peritonitisCancer of unknown primary (cup)MedicineOverall survivalPriority journalSurvival timeUnivariate analysisTissue microarraybiologyUnknown primaryHematologyClassificationPrognosisImmunohistochemistryPtenRetrospective studyOncologyIntracellular signalingImmunohistochemistryFemaleCyclin d1Cancer tissueProtein p21HumanSignal Transductionmedicine.medical_specialtyTranslational studyMajor clinical studyCancer mortalityAdenocarcinomaArticleCyclin D1Disease associationInternal medicineTissue array analysisPTENHumansHuman tissueProtein kinase BPI3K/AKT/mTOR pathwayCancer prognosisSurvival predictionDigestive system cancerbusiness.industryAkt/PKB signaling pathwayAktCancer of unknown primary siteProto-oncogene proteins c-aktRps6Protein kinase bTissue Array Analysisbiology.proteinProtein expressionProgression free survivalProtein s6Neoplasms Unknown PrimarybusinessTissue preparationProto-Oncogene Proteins c-aktAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.

2010

Nucleoside transporter proteins are specialized proteins that mediate the transport of nucleosides and nucleoside analog drugs across the plasma membrane. The human equilibrative nucleoside transporter 1 (hENT1) is a member of these proteins and mediates cellular entry of gemcitabine, cytarabine, and fludarabine. The hENT1 expression has been demonstrated to be related with prognosis and activity of gemcitabine-based therapy in breast, ampullary, lung, and pancreatic cancer. We investigated the immunohistochemical expression of hENT in tumor samples from 111 patients with resected gastric adenocarcinoma, correlating these data with clinical parameters and disease outcomes. None of the patie…

OncologyMaleSettore MED/06 - Oncologia MedicaPhysiologymedicine.medical_treatmentClinical BiochemistryNucleoside transporterEquilibrative nucleoside transporter 1Cohort StudiesMedicineNeoplasm MetastasisAged 80 and overbiologyMiddle AgedPrognosisImmunohistochemistryFludarabineSurvival RateDisease ProgressionFemalemedicine.drugAdultmedicine.medical_specialtyNucleoside transporterAntineoplastic AgentsAdenocarcinomaDisease-Free SurvivalEquilibrative Nucleoside Transporter 1Predictive Value of TestsStomach NeoplasmsPancreatic cancerInternal medicineBiomarkers TumorHumansSurvival rateAgedRetrospective Studiesbusiness.industryCancerCell Biologymedicine.diseaseGemcitabineRadiation therapyDrug Resistance NeoplasmGastric MucosaImmunologybiology.proteinNeoplasm Recurrence LocalbusinessJournal of cellular physiology
researchProduct

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

2012

BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC. In this trial, 602 patients with well-preserved liver function (>95% Child-Pugh A) were randomized to receive either sorafenib 400mg or matching placebo orally b.i.d. on a continuous basis. Because HCC is a heterogeneous disease, baseline patient characteristics may affect individual responses to treatment. In a comprehensive series of exploratory subgroup analyses, data from the SHARP trial were analyzed to discern if baseline patient characteristics influenced the efficacy and safety o…

OncologyMaleTime FactorsMedizinKaplan-Meier EstimateSeverity of Illness Indexlaw.inventionAntineoplastic Agent0302 clinical medicineRandomized controlled triallawMedicineOverall survivalDisease control rateFatigueTime to progressionHazard ratioLiver Neoplasmshepatocellular carcinomaMiddle AgedSorafenib3. Good healthTumor BurdenAlcoholismSubset analysesLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaDisease Progression030211 gastroenterology & hepatologyFemaleHand-Foot SyndromeHumanmedicine.drugPhenylurea CompoundSorafenibDiarrheaNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularTime FactorAntineoplastic AgentsPlacebo03 medical and health sciencesHepatitis B ChronicInternal medicineHumansneoplasmsAgedNeoplasm StagingProportional Hazards ModelsPerformance statusHepatologybusiness.industryPhenylurea CompoundsHepatitis C Chronicmedicine.diseasedigestive system diseasesSurgeryClinical trialProportional Hazards ModelLiver functionbusinessJournal of hepatology
researchProduct

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

2021

Not Available

OncologyMalechronic B cell leukemiachronic lymphocytic leukemia; ibrutinib; 4-factor score; prognosis.Datasets as TopicSeverity of Illness Indexchemistry.chemical_compoundPiperidinesRetrospective analysisMulticenter Studies as TopicChronicLeukemiaHematologyMiddle AgedPrognosisLymphocyticProgression-Free SurvivalIbrutinibFemalemedicine.medical_specialtyreal-word studyFactor scoreAntineoplastic AgentsAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival AnalysisRisk AssessmentNOibrutinibInternal medicineSeverity of illnessmedicineHumansProgression-free survivalProtein Kinase InhibitorsSurvival analysisAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelAdenineB-CellReproducibility of ResultsRetrospective cohort studyAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Survival Analysis; Severity of Illness IndexLeukemia Lymphocytic Chronic B-CellSurvival AnalysisSettore MED/15 - MALATTIE DEL SANGUEchemistrybusinesschronic lymphocytic leukaemiaFollow-Up Studies
researchProduct

Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study

2016

<b><i>Purpose:</i></b> The present study aims to evaluate the efficacy of cabazitaxel in combination with prednisone treatment in Italian patients affected by hormone-refractory metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel plus prednisone. <b><i>Methods:</i></b> Thirty patients with mCRPC were enrolled between June 2013 and January 2016 (the last follow-up was in January 2016). Cabazitaxel was used according to the summary of product characteristics and administered at a dose of 25 mg/m<sup>2</sup> every 3 weeks plus oral prednisone at a dose of 5-mg tablets twice a day continuously. The…

OncologyMalemedicine.medical_specialtyCancer Research030232 urology & nephrologyProstate neoplasmAntineoplastic AgentsDocetaxelCastration resistantAdenocarcinomaTaxaneSingle CenterAntineoplastic Agent03 medical and health sciencesProstate cancer0302 clinical medicinePrednisoneInternal medicineTaxoidmedicineClinical endpointHumansProspective StudiesAgedResponse rate (survey)GynecologyCabazitaxelbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseMetastatic castration-resistant prostate cancerProspective StudieProstatic Neoplasms Castration-ResistantDocetaxelOncologyCabazitaxel030220 oncology & carcinogenesisChemotherapy regimenDisease ProgressionPrednisoneTaxoidsbusinessmedicine.drugHuman
researchProduct